A monkeypox virus recombinant multi-component subunit vaccine and its preparation method and application
By developing a multi-component subunit vaccine containing monkeypox virus recombinant protein, combined with adjuvant and expression system, the safety and effectiveness of existing vaccines have been solved, and efficient protection of monkeypox virus and simplified production process has been achieved.
Patent Information
- Application Number
- CN202411249068.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-09-06
AI Technical Summary
The existing monkeypox virus vaccine has safety problems and unknown effectiveness, and the existing nucleic acid vaccine is difficult to control bioavailability and expression efficiency, resulting in unstable immune response and lack of safe and effective vaccines against monkeypox virus.
Develop a recombinant multi-component subunit vaccine of monkeypox virus, including monkeypox virus recombinant proteins such as A35, B6R, E8L, A29, M1R, H3L, etc., combined with aluminum hydroxide and CpG adjuvant, through the yeast and E. coli expression system Optimize vaccine composition and preparation process and design fusion proteins such as A35-M1R to improve immunogenicity.
It has achieved efficient protection effect on monkeypox virus, optimized vaccine composition and preparation cycle, provided cross-neutralizing antibodies, simplified the production process, and provided a theoretical basis for mRNA vaccine design.
Smart Images

Figure CN118767123B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to a recombinant multi-component subunit vaccine of monkeypox virus and a preparation method and application thereof. Background Art
[0002] Monkeypox virus belongs to the genus Orthopoxvirus of the family Poxviridae. The genus Orthopoxvirus includes 12 viruses such as smallpox virus (VARV), cowpox virus (CPXV), and vaccinia virus (VACV). Like other orthopoxviruses, MPXV has two infection modes: intracellular mature virions (IMV) and extracellular enveloped virions (EEV), both of which are infectious and can induce monkeypox disease. Therefore, it is generally believed that subunit vaccines designed for the infection mode of monkeypox virus need to consider both IMV and EEV virions. The better suggestion is that it should contain at least one antigen on both IMV and EEV.
[0003] Studies have shown that the amino acid sequences of viral antigens of the genus Orthopoxvirus are highly similar, so there is a cross-protective immune function between antigens, and the effective protection of smallpox vaccine against MPXV is 85%. So far, the U.S. Food and Drug Administration (FDA) has approved two smallpox vaccines (ACAM2000 and JYNNEOS) for emergency immunization against monkeypox disease. Unfortunately, the attenuated vaccine ACAM2000 has certain safety issues, and the adverse reactions it causes are particularly obvious in immunocompromised individuals. In addition, the specific effect of the JYNNEOS vaccine in preventing monkeypox virus infection is still unknown. At present, recombinant subunit vaccines specific for monkeypox virus have not yet been launched on the market. There is an urgent need for safe, effective and easy-to-produce vaccines in society. Considering the history of smallpox vaccination in my country and the prevalence of monkeypox, combined with the current needs of biosafety, public health and epidemic prevention and control, it is urgent to develop monkeypox vaccines.
[0004] Previous studies have shown that DNA-based smallpox vaccines, or vaccines developed using A27L, L1R, A33R, and B5R of the smallpox virus, can effectively protect non-primates from lethal VACV challenges. Most vaccines currently in the development stage are nucleic acid vaccines. However, nucleic acid vaccines for multi-antigen combined immunization cannot effectively control the bioavailability and expression efficiency of each component, making it difficult to achieve a sustained balanced immune response between different immunogens, which poses a huge challenge to the stability and maximization of vaccine protection. Therefore, it is necessary to develop subunit vaccines to improve the stability of these viruses and the technology of antigen expression to further improve their efficacy. Summary of the invention
[0005] In view of the technical problems existing in the prior art, especially the problems existing in the development of the existing coronavirus mucosal vaccine, the present invention proposes a recombinant multi-component subunit vaccine of monkeypox virus and its preparation method and application, wherein the recombinant multi-component subunit vaccine of monkeypox virus comprises a recombinant protein of monkeypox virus and an adjuvant, wherein the recombinant protein of monkeypox virus comprises one or more of A35, B6R, E8L, A29, M1R, H3L, A35-A29, and A35-M1R. The MPXV vaccine (MPXV6, MPXV5, MPXV4, MPXV3a, MPXV3b, MPXVFa, and MPXV2a) in the present invention provides cross-neutralizing antibodies against VACV, and the 2 antigens MPXV2a (A35, M1R) can provide complete protection. The present invention uses the 2 antigens fused MPXVFa (A35-M1R) to effectively optimize the vaccine composition and simplify the preparation cycle and process and has a highly effective protection effect; the present invention provides a reference for the research and development of the preparation of MPXV recombinant subunit vaccine.
[0006] According to the first aspect of the technical solution of the present invention, the monkeypox virus recombinant multi-component subunit vaccine comprises a monkeypox virus recombinant protein and an adjuvant, and the monkeypox virus recombinant protein comprises one or more of A35, B6R, E8L, A29, M1R, H3L, A35-A29, and A35-M1R. Further, the monkeypox virus recombinant protein comprises 2-6 of A35, B6R, E8L, A29, M1R, H3L, A35-A29, and A35-M1R.
[0007] In certain embodiments, the adjuvant comprises aluminum hydroxide adjuvant, CpG adjuvant.
[0008] According to the second aspect of the technical solution of the present invention, the present invention also provides a biological material related to the above-mentioned monkeypox virus recombinant multi-component subunit vaccine, which is any one of the following B1) to B8):
[0009] B1) a nucleic acid molecule encoding the monkeypox virus recombinant protein as described above;
[0010] B2) an expression cassette containing the nucleic acid molecule described in B1);
[0011] B3) a recombinant vector containing the nucleic acid molecule described in B1);
[0012] B4) a recombinant vector containing the expression cassette described in B2);
[0013] B5) a recombinant microorganism containing the nucleic acid molecule described in B1);
[0014] B6) a recombinant microorganism containing the expression cassette described in B2);
[0015] B7) a recombinant microorganism containing the recombinant vector described in B3);
[0016] B8) A recombinant microorganism containing the recombinant vector described in B4).
[0017] In certain embodiments, the vectors include yeast expression vectors and Escherichia coli prokaryotic expression vectors.
[0018] In certain embodiments, the recombinant microorganism comprises an engineered bacterium.
[0019] In certain embodiments, the vector comprises yeast and E. coli.
[0020] In certain embodiments, the yeast is a glycoengineered yeast strain.
[0021] According to the third aspect of the technical solution of the present invention, the present invention also provides a method for preparing the above-mentioned recombinant multi-component subunit vaccine of monkeypox virus, comprising:
[0022] Obtaining the coding gene; transforming the coding gene into expression cells; expressing the monkeypox virus recombinant protein in the expression cells; and purifying the monkeypox virus recombinant protein.
[0023] According to the fourth aspect of the technical solution of the present invention, the present invention finally provides the use of the above-mentioned monkeypox virus recombinant multi-component subunit vaccine or the above-mentioned biological material or the above-mentioned preparation method in any of the following c1-c4:
[0024] c1) Prevention or treatment of diseases caused by monkeypox virus infection;
[0025] c2) prevention or treatment of monkeypox virus infection;
[0026] c3) preparing a pharmaceutical composition for preventing or treating diseases caused by infection with monkeypox virus;
[0027] c4) preparing a pharmaceutical composition for preventing or treating infection by monkeypox virus;
[0028] Said c1-c2 are for non-therapeutic purposes; said pharmaceutical composition comprises an adjuvant.
[0029] Compared with the prior art, the monkeypox virus recombinant multi-component subunit vaccine of the present invention and its preparation method and application have the following beneficial effects:
[0030] 1. The present invention systematically studies and designs 9 groups of multi-component subunit candidate vaccines containing MPXV, which contain various combinations of encoding 4 IMV surface proteins (A29, M1R, H3L and E8L) and 2 EEV surface proteins (A35 and B6R); the present invention conducts a more comprehensive combination system study on the 6 antigens on the surface of MPXV, and selects the Escherichia coli prokaryotic expression system and the yeast eukaryotic expression system to express the MPXV recombinant protein according to the theoretical expression form of the protein, so as to ensure better antigenicity of the protein.
[0031] 2. The present invention designs fusion proteins (A35-M1R, A35-A29) to improve the immunogenicity of subunit vaccines, optimize vaccine composition, and simplify the vaccine preparation cycle and process. The central regions of the genomes of all orthopoxviruses show more than 90% homology, and the homology between MPXV and VACV is as high as 96.3%, which indicates that they are highly similar genetically. The MPXV candidate antigen (A35, B6R, E8L, A29, M1R, H3L) genes selected by the present invention are highly conserved with orthopoxvirus homologous genes (including VACV and smallpox virus).
[0032] 3. The MPXV subunit candidate vaccines (MPXV6, MPXV5, MPXV4, MPXV3a, MPXV3b, MPXVFa, MPXV2a, MPXVFb, MPXV2b) have cross-protection against orthopoxviruses; the experimental results show that the results of the VACV live virus neutralizing antibody detection prove that the MPXV subunit candidate vaccines (MPXV6, MPXV5, MPXV4, MPXV3a, MPXV3b, MPXVFa and MPXV2a) of the present invention can induce effective VACV neutralizing antibodies. The neutralizing antibody titers induced by the MPXVFb and MPXV2b vaccines were about 1:380, and the neutralizing activity was relatively low. The MPXVFa and MPXV2a vaccine groups with protective antigens A35 and M1R induced high levels of neutralizing antibody titers of 1:3763 and 1:3727; the neutralizing activity of the MPXVFb and MPXV2b vaccine groups with protective antigens A35 and A29 was lower than 1:380, indicating that M1R is a key antigen in the vaccine composition, but A29 may play a smaller role in the vaccine composition than M1R.
[0033] 4. In the present invention, there is no significant difference in the neutralizing antibody titer detected in the serum of mice immunized with MPXVFa (A35-M1R) and the antibody titer in the serum of mice immunized with MPXV2a (A35, M1R), indicating that the A35-M1R fusion protein, as a protective immune antigen, can provide the same high level of protection effect and has certain advantages in optimizing vaccine composition and simplifying the vaccine preparation cycle and process.
[0034] 5. The present invention shows that the 2-antigen group MPXV2a (A35, M1R) and the fusion group MPXVFa (A35-M1R) can produce the same high level of neutralizing antibody titers as the 6-antigen group, indicating that A35 and M1R are indispensable components of monkeypox vaccines. These research results of the present invention provide a valuable theoretical basis for the design and preparation of mRNA vaccines, and suggest that the A35-M1R combination antigen design can also be considered when designing mRNA vaccines to enhance the protective effect while further simplifying the preparation process of mRNA vaccines.
[0035] 6. The experimental results of the present invention show that subunit vaccines encoding seven different components, A35, B6R, M1R, A29, E8L, H3L (MPXV6, MPXV5, MPXV4, MPXV3a, MPXV3b, MPXVFa and MPXV2a), can effectively stimulate high levels of corresponding antibodies and effectively neutralize live virus infection in cell culture. These results show that MPXV vaccines (MPXV6, MPXV5, MPXV4, MPXV3a, MPXV3b, MPXVFa and MPXV2a) provide cross-neutralizing antibodies against VACV. Moreover, the 2 antigens MPXV2a (A35, M1R) can provide complete protection. The use of 2 antigens fused MPXVFa (A35-M1R) can effectively optimize the vaccine composition and simplify the preparation cycle and process and has a highly effective protection effect.
[0036] 7. The present invention provides a reference for the research and development of MPXV recombinant subunit vaccines. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1-A to Figure 1-F They are the design, purification and identification of MPXV recombinant proteins A29, H3L, M1R, B6R, A35 and E8L. Figure 1-A It is the pattern diagram of MPXV A29, H3L, M1R, B6R, A35, and E8L proteins; Figure 1-B Design expression pattern diagram for recombinant protein: H3L, M1R, A29 proteins remove transmembrane and intracellular regions, add His-tag at the C-terminus, and express using prokaryotic system; E8L, A35, B6R remove transmembrane and intracellular regions, add yeast secretion signal peptide at the N-terminus, add His-tag at the C-terminus, and express through Pichia pastoris system; Figure 1-C and Figure 1-D SDS-PAGE, Western Blot analysis and verification of A29, H3L, and M1R proteins; Figure 1-E and Figure 1-F SDS-PAGE, Western Blot analysis and verification of B6R, A35, and E8L.
[0038] Figure 2-A to Figure 2-E They are respectively for the design, purification and identification of MPXV fusion proteins A35-M1R and A35-A29. Figure 2-A The schematic diagrams of MPXV fusion proteins A35-M1R and A35-A29; Figure 2-B and Figure 2-C The A35-M1R protein was analyzed and verified by SDS-PAGE and Western Blot respectively; Figure 2-D SDS-PAGE analysis of A35-A29 proteins; Figure 2-E Figure 1 is the transmission electron microscopy analysis diagram of A35-A29, wherein Figure a is the transmission electron microscopy analysis result of A29 protein, Figure b is the transmission electron microscopy analysis result of A35 protein, and Figure c is the transmission electron microscopy analysis result of A35-A29 fusion protein.
[0039] Figure 3-A to Figure 3-E The antigen-specific antibody titers of BALB / c mice immunized with vaccines of different MPXV antigen groups were evaluated. A35, A29, H3L, E8L, B6R, M1R, A35-A29 and A35-M1R were configured into 6 / 5 / 4 / 3 / 2 antigen groups and fusion antigen groups. Aluminum hydroxide and CpG were used as double adjuvants to immunize mice, and aluminum hydroxide and CpG were used as control groups. Mouse sera were collected at 2, 4, and 6 weeks, and the antigen-specific antibody titers were evaluated by indirect ELISA analysis. Specifically, Figure 3-A Schematic diagram of different antigen components in each immune group; Figure 3-B This is a schematic diagram of the research plan for vaccine immunization of mice; Figure 3-C The antibody titer for binding after two weeks of immunization; Figure 3-D The antibody titer for the second immunization is two weeks later; Figure 3-E The binding antibody titer is the titer of three immunizations and two weeks later. One-way ANOVA P value: ****: P < 0.0001.
[0040] Figure 4-A and Figure 4-B The neutralizing antibody titers against VACV real virus were evaluated by immunizing mice with A35, A29, H3L, E8L, B6R, M1R, A35-A29 and A35-M1R for two weeks. One-way ANOVA P value; *: P < 0.05; **: P < 0.01; ***: P < 0.001; ****: P < 0.0001. Specifically: Figure 4-A The neutralizing antibody titers are for multiple antigen groups. The P values for t-test analysis only indicate the groups with differences. Figure 4-B It is a fusion antigen group and the corresponding double antigen group.
[0041] Figure 5-A and Figure 5-B They are safety assessments. Figure 5-ATo show the weight change curve of mice after immunization; Figure 5-B To show the histopathological changes of heart, liver, spleen, lung and kidney tissues observed under optical microscope. DETAILED DESCRIPTION
[0042] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0043] In the present invention, with reference to the data of the study on the live attenuated strain vaccine of smallpox virus, the six antigens on the surface of MPXV are studied more comprehensively to explore the most economical and efficient subunit vaccine combination; A29, H3L, M1R, and E8L are located on the intracellular mature virus (IMV). After the virus particles mature, the IMV is directly released, and A29, H3L, M1R, and E8L are released accordingly without the need for glycosylation and other modifications through the endoplasmic reticulum and Golgi apparatus. In order to achieve efficient expression and purification of proteins, the present invention uses the Escherichia coli prokaryotic expression system to express and prepare the target proteins A29, H3L, M1R, and E8L. The prokaryotic system ensures the natural expression form of the target protein and effectively shortens the preparation cycle.
[0044] Studies have shown that subunit vaccines have the advantages of fast development, high safety, and large-scale industrial mass production. These advantages make subunit vaccines a new hot spot and development direction in infectious disease prevention research. The development of a subunit vaccine for MPXV is highly feasible, but the rational selection of protective antigens is also crucial. VACV has a large selection of protective antigens and a large candidate range. Multiple proteins including A27, L1R, H3L, E8L, A35, D8, M1R, A33 and B5R can be selected. The present invention's research shows that the ideal MPXV subunit vaccine should contain antigens of two infection forms, that is, both IMV antigens and EEV antigens.
[0045] In the present invention, A35 and B6R are located on the enveloped virion (EEV). EEV is modified by the endoplasmic reticulum and Golgi apparatus on the basis of IMV to obtain a layer of viral membrane; in this process, the protein is glycosylated. The monkeypox subunit vaccines currently studied mostly use Escherichia coli as the production system, and the prokaryotic system can no longer meet the glycosylation modification of A35 and B6R proteins during the formation process; mammalian cells used for protein expression have glycosylation modification capabilities, but the mammalian production platform has a long production cycle and relatively high costs; yeast, as a simple eukaryotic organism, has a certain ability to modify proteins after translation, and has a fast growth rate and low production cost, making it an ideal protein preparation platform; however, the N-glycosylation modification of yeast is excessive mannosylation modification, which will cause protein epitope shielding and higher-order structural changes, thereby affecting the immunogenicity and protective effect of the vaccine. The present invention transforms yeast glycosylation engineering so that yeast has the glycosylation modification ability of mammalian cells, while taking into account the advantages of rapid growth, low cost and strong emergency response capability; furthermore, the present invention uses the glycosylation engineering yeast system GJK30 (preservation number 19488) constructed by the applicant in the early stage (an engineered yeast strain for glycoprotein preparation and its construction method. Patent authorization number: ZL202010331661.8. Authorization date: 2024.02.13.) to achieve the expression and preparation of A35 and B6R proteins, ensure that the antigen protein is correctly folded and expressed in a post-translational modification (such as glycosylation) manner in eukaryotic cells, and well ensure the antigenicity.
[0046] In order to improve the immunogenicity of subunit vaccines, optimize vaccine composition and simplify vaccine preparation cycle and process, the present invention couples A35 and A29 by taking advantage of the characteristics of natural dimers of A35 (EEV protein) and the characteristics of natural trimers of A29 (IMV protein) to form (2+3)n nanoparticles; at the same time, by taking advantage of the characteristics of natural dimers of A35 (EEV protein), A35 and A29 are coupled with M1R (IMV protein) protein with smaller molecular weight to construct a fusion of two protein dimers to prepare subunit vaccines.
[0047] The present invention uses glycosyl engineering yeast and Escherichia coli to prepare six MPXV recombinant proteins A35, B6R, E8L, A29, M1R, H3L and multimeric fusion proteins (A35-A29, A35-M1R); one of the inventive points of the present invention is that the MPXV6 vaccine group includes 6 proteins, namely A35, B6R, E8L, A29, M1R, H3L; the MPXV6 vaccine group includes 5 proteins, namely A35, B6R, A 29, M1R, H3L; MPXV4 vaccine group includes 4 proteins, namely A35, B6R, A29, M1R; MPXV3a vaccine group includes 3 proteins, namely A35, B6R, M1R; MPXV3b vaccine group includes 3 proteins, namely A29, A35, M1R; MPXV2a vaccine group includes 2 proteins, namely A35, M1R; MPXV2b vaccine group includes 2 proteins, namely A35, A29. Another inventive point of the present invention is to design, construct and prepare multimeric fusion proteins (A35-A29, A35-M1R), that is, to express the fusion of A35 protein and A29 protein, and obtain A35-A29 fusion protein, namely MPXVFb vaccine group; similarly, the present invention prepares A35-M1R fusion protein, namely MPXVFa vaccine group. These proteins were combined with aluminum hydroxide adjuvant and CpG adjuvant to develop nine different combinations of multi-component subunit vaccine candidates to explore the effectiveness and safety of different vaccines. Figure 3-A shown.
[0048] Materials and methods (strains, plasmids, materials):
[0049] Mammalian cells used for protein expression have the ability to modify glycosylation, but the production platform of mammals has a long production cycle and relatively high cost. Yeast, as a simple eukaryotic organism, has a certain ability to modify proteins after translation, and has a fast growth rate and low production cost, making it an ideal protein preparation platform. However, the N-glycosylation modification of yeast is excessive mannosylation modification, which will cause protein epitope shielding and higher-order structural changes, thereby affecting the immunogenicity and protective effect of the vaccine. This laboratory has modified yeast glycosylation through yeast engineering, so that yeast has the ability to modify glycosylation of mammalian cells, while taking into account the advantages of fast growth, low cost and strong emergency response capabilities. Therefore, the glycosylation engineering yeast system constructed by the research team in the early stage was used (see: An engineered yeast strain for glycoprotein preparation and its construction method, patent authorization number ZL202010331661.8.), and the glycosylation engineering yeast system was preserved by this laboratory. Trans 5α Escherichia coli competent cells used for cloning were purchased from Beijing Quanshijin Biotechnology Co., Ltd., and BL21 (DE3) competent cells were purchased from Nanjing Vazyme Biotechnology Co., Ltd. Plasmids: pPICZαA plasmid, used to construct recombinant expression plasmids pPICZαA-A35, pPICZαA-B6R, pPICZαA-E8L, pPICZαA-A35-M1R, pPICZαA-A35-A29, preserved by this laboratory; pET28a plasmid, used to construct recombinant expression plasmids pET28a-A29, pET28a-H3L, pET28a-M1R, preserved by this laboratory. BS-C-1 (ATCC, CCL-26) cells and vaccinia virus (VACV) WR strain (GenBank: AY243312.1) used for neutralization detection were from the State Key Laboratory of Biosafety of Pathogenic Microorganisms. A35 monoclonal antibody, E8L monoclonal antibody and M1R monoclonal antibody were purchased from Tianjin KAMD Technology Development Co., Ltd.; B6R monoclonal antibody was prepared in our laboratory; horseradish peroxidase (HRP)-labeled goat anti-mouse antibody was purchased from Abcam; HRP-labeled anti-His tag monoclonal antibody was purchased from Sigma.
[0050] Example 1: Cloning and expression of key antigen genes of monkeypox virus candidate vaccine.
[0051] The full-length amino acid sequences of A29, M1R, H3L, E8L, A35, and B6R were obtained from the NCBI database (www.ncbi.nlm.nih.gov). The protein transmembrane regions were predicted using the online prediction website TMHMM-2.0, and the protein signal peptides were predicted using SignalP-6.0 ( Figure 1-A), the gene transmembrane region and intracellular region sequences were removed by prediction results, and His-tag was added to the C-terminus of the coding sequence. The amino acid sequence was handed over to Sangon Biotech (Shanghai) Co., Ltd. for gene sequence optimization and synthesis. In order to simplify the preparation process of subunit vaccines, the two antigens were fused into one antigen and improve immunogenicity. A35 and A29 were coupled to form nanoparticles by taking advantage of the characteristics of the natural dimer of A35 (EEV protein) and the natural trimer of A29 (IMV protein); at the same time, the characteristics of the natural dimer of A35 (EEV protein) were taken advantage of to fuse with the M1R (IMV protein) protein with a smaller molecular weight to form two protein dimers to prepare subunit vaccines. The A29, H3L, and M1R genes were cloned into the Not I and Nco I sites of the pET28a vector to construct the pET28a-A29, pET28a-H3L, and pET28a-M1R expression vectors driven by the T7 promoter. Plasmids pET28a-A29, pET28a-H3L, and pET28a-M1R were transformed into Escherichia coli competent cells BL21. A35, B6R, E8L, A35-A29, and A25+M1R genes were cloned into the XhoI and NotI sites of the pPICZαA vector to construct pPICZαA-A35, pPICZαA-B6R, pPICZαA-E8L, PICZαA-A35-A29, and pPICZαA-A35-M1R expression vectors driven by the AOX I promoter. Plasmids pPICZαA-A35, pPICZαA-B6R, pPICZαA-E8L, PICZαA-A35-A29, and pPICZαA-A35-M1R linearized with BglII were transformed into glycosyl engineering yeast competent cells by electrochemical transformation ( Figure 1-B Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot were used to detect the target protein, and HRP-labeled anti-His antibody (dilution ratio of 1:2500) was used to screen positive clones expressed in Escherichia coli and yeast.
[0052] Example 2: Protein expression and purification.
[0053] (1) Yeast eukaryotic system fermentation and target protein purification.
[0054] The engineered strains with high expression of the target protein pPICZαA-A35, pPICZαA-B6R, pPICZαA-E8L, pPICZαA-A35-A29, and pPICZαA-A35-M1R obtained through screening were inoculated into 2.5 mL YPD liquid culture medium at 25°C for recovery. After 72 h of test tube culture, all were inoculated into 200 mL YPD liquid culture medium for expanded culture.
[0055] A35, B6R, and E8L were fermented on a 5L scale. 27 hours after inoculation, the fermentation tank speed was increased from 400rpm to 800rpm, and the ventilation volume was adjusted from 5 to 10. After the dissolved oxygen recovered, feeding began, and the feeding rate was set to 0.5 mL / min. The temperature was adjusted from 25°C to 22°C. The wet bacteria weight, OD value, and yeast growth status were subsequently monitored at 0h, 12h, and 24h of induction, and the yeast morphology was identified by microscopic examination. The fermentation was terminated and the bacteria were harvested after 30h of induction. The A35-A29 and A35-M1R high-expression engineering strains were amplified by shaking flasks, inoculated with BMGY (Buffered Minimal Glycerol-complex Medium) liquid culture medium (5% inoculation amount), cultured in a shaking incubator at 25°C, induced with 1% methanol, 24h / time, and induced for 72h.
[0056] According to the different properties of the target protein, select the appropriate purification system and purification scheme, and finally obtain the high-purity target protein through weak cation exchange chromatography, hydrophobic chromatography, strong anion exchange chromatography, strong cation exchange chromatography, gel exclusion chromatography, and nickel column adsorption chromatography.
[0057] (2) Escherichia coli prokaryotic system fermentation and target protein purification.
[0058] The strains pET28a-A29, pET28a-H3L, and pET28a-M1R containing the target protein gene were amplified in shake flasks, and the target protein was expressed and purified from the Escherichia coli prokaryotic expression system. The specific steps are as follows:
[0059] Pick a single clone of the target strain from the LB / Kan plate and inoculate it into 3mL LB / Kan liquid medium, then place it in a 37℃ constant temperature incubator for continuous culture for 10h. After 10h, when the bacterial solution becomes turbid, transfer 3mL of the bacterial solution to 100mL LB / Kan liquid medium and place it in a 37℃ constant temperature incubator for culture for 8h. Then transfer 100mL of the bacterial solution to No. 1 medium at a 1% inoculation rate, inoculate a total of 2L, and continue to culture in a 37℃ constant temperature incubator for 3h. After 3h, sample 5mL of the bacterial solution in the clean bench to measure its OD600 value, and use No. 1 blank medium as a control to deduct the background. After repeated tests, the OD600 value is about 0.6-0.8. When the OD value of the bacterial solution is in the correct range, add IPTG with a final concentration of 1mM and place it at 37℃ or 25℃ to induce the expression of the target protein.
[0060] To purify A29 and H3L, cells were first collected and resuspended in water, and the supernatant was collected after ultrasonic disruption, and the protein was purified by Ni affinity chromatography and gel exclusion chromatography. To purify M1R, cells were collected, resuspended, crushed and centrifuged as described above, and the precipitate was denatured with 8M urea, gradiently diluted and renatured, and the renatured sample was purified by Ni affinity chromatography and gel exclusion chromatography.
[0061] (3) Characterization and quantification of the recombinant target protein.
[0062] After purification, the target proteins A35, B6R, E8L, and A35-M1R showed double bands in electrophoresis. Monoclonal antibodies were purchased for Western Blot identification of the target recombinant proteins. The monoclonal antibody was used as the primary antibody after dilution of 1:2500; the HRP goat anti-mouse IgG antibody was used as the secondary antibody after dilution of 1:2500. A29-A35 showed multiple electrophoretic bands in the non-reduced state, and it was suspected that nanoparticles were formed. Therefore, the purified samples of A29-A35 were observed for nanoparticles by transmission electron microscopy. First, negative staining was performed. The sealing film was spread flat on the glass slide, and the copper mesh clip was placed on the sealing film with tweezers. 10μL of A29-A35 protein sample was taken with a pipette and dropped on the copper mesh, and then the sample was left to stand for 10 minutes, and the excess liquid was removed with filter paper. Then 10μL of 3% uranyl acetate was taken with a pipette and dropped on the copper mesh, and the sample was left to stand for 3 minutes, and the excess staining liquid was removed with filter paper. It was placed at room temperature for 10 minutes to allow the copper mesh to dry naturally. The samples were observed and photographed using a transmission electron microscope. The concentration of the purified proteins was determined using the ThermoScientific Pierce BCA protein quantification kit.
[0063] result: The A29, M1R, and H3L coding genes were inserted into the prokaryotic expression vector pET28a, respectively. The theoretical molecular weights of the recombinant proteins A29, M1R, and H3L were estimated (Table 1), and SDS-PAGE identification showed that A29, M1R, and H3L were expressed in Escherichia coli. The purified recombinant proteins were further verified by SDS-PAGE and Western Blot ( Figure 1-C , Figure 1-D ), the results showed that these proteins and their specific antibodies maintained binding activity, indicating that their structures were correct. A29, M1R, and H3L were purified to obtain high-purity protein samples, which can be used for subsequent vaccine immunity research.
[0064] The A35, B6R, and E8L coding genes were inserted into the eukaryotic expression vector pPICZαA, respectively. The glycosylation engineering yeast, which is unique to our laboratory and has the ability to modify glycosylation in mammalian cells, and has the advantages of rapid growth, low cost, and strong emergency response capabilities, was selected to express the recombinant protein. The theoretical molecular weight and number of glycosylation sites of the recombinant proteins A35, B6R, and E8L were estimated (Table 1), and SDS-PAGE identification showed that A35, B6R, and E8L were expressed in the glycosylation engineering yeast. The purified recombinant protein was further verified by SDS-PAGE and Western Blot ( Figure 1-E , Figure 1-F ), the results showed that these proteins and their specific antibodies maintained binding activity, indicating that their structures were correct. A35, B6R, and E8L were purified to obtain high-purity protein samples, which can be used for subsequent vaccine immunity research.
[0065] Table 1 Summary of information on MPXV vaccine candidate antigens
[0066]
[0067] A35-M1R, A35-A29( Figure 2-A ) encoding genes were inserted into the eukaryotic expression vector pPICZαA, and the glycosyl engineering yeast was selected to express the recombinant protein. SDS-PAGE identification showed that A35-M1R was expressed in the glycosyl engineering yeast. The purified recombinant protein was further verified by SDS-PAGE and Western Blot. Figure 2-B , Figure 2-C ), the results showed that the A35-M1R protein and its specific antibody maintained binding activity, indicating that the A35-M1R fusion antigen was successfully purified. Figure 2-D ) The purified samples of A29-A35 were identified. Since A35 is a trimer and A29 is a dimer, the samples showed multiple bands in the non-reduced state. It was speculated that A29-A35 formed nanoparticles. The electron microscopy results showed that the fusion protein A29-A35 formed nanoparticles of about 20nm ( Figure 2-E ), indicating that the A35-M1R fusion antigen was successfully purified, and A35-M1R and A35-A29 were purified to obtain high-purity protein samples, which can be used for subsequent vaccine immunity research and development.
[0068] Example 3: Evaluation of the immunogenicity of MPXV vaccine candidates.
[0069] This embodiment combines Figure 3-A to Figure 3-E Give a description. Figure 3-A to Figure 3-EThe antigen-specific antibody titers of BALB / c mice immunized with vaccines of different MPXV antigen groups were evaluated. A35, A29, H3L, E8L, B6R, M1R, A35-A29 and A35-M1R were configured into 6 / 5 / 4 / 3 / 2 antigen groups and fusion antigen groups. Aluminum hydroxide and CpG were used as double adjuvants to immunize mice, and aluminum hydroxide and CpG were used as control groups. Mouse sera were collected at 2, 4, and 6 weeks, and the antigen-specific antibody titers were evaluated by indirect ELISA analysis. Specifically, Figure 3-A Schematic diagram of different antigen components in each immune group; Figure 3-B This is a schematic diagram of the research plan for vaccine immunization of mice; Figure 3-C The antibody titer for binding after two weeks of immunization; Figure 3-D The antibody titer for the second immunization is two weeks later; Figure 3-E The binding antibody titer was measured after three immunizations and two weeks. One-way ANOVA P value: ****: P < 0.0001.
[0070] (1) Female specific pathogen-free BALB / C mice, 17-21 g, 6 weeks old, were purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd. and housed in the Animal Center of Beijing Institute of Bioengineering. All animal experiments and research and development strictly abided by the guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Ethics and Use Committee of Beijing Institute of Bioengineering. The experimental animal ethics number is IACUC-DWZX-2020-039.
[0071] SPF mice were housed in specific pathogen-free (SPF), individually ventilated cages (IVC) and fed a standardized diet. After acclimating to the new environment for one week, 10 mice were randomly divided into groups. A35, A29, H3L, E8L, B6R, M1R, A35-A29 and A35-M1R proteins were combined in various forms or protein fusion coupling, with aluminum hydroxide and CpG2006 as adjuvants, and 9 experimental groups were designed ( Figure 3-A ) and a control group were immunized. The control group mice were immunized with aluminum hydroxide and CpG2006 only. BALB / c mice were immunized by intramuscular injection (100 μL / mouse, 10 μg / antigen). The mice were immunized on days 0, 14, and 28. Blood was collected from the orbital venous sinus before immunization and 13 days after the first, second, and third immunizations ( Figure 3-B The collected blood was placed at 4°C overnight, centrifuged at 4°C, 6500 rpm for 10-15 min, and the serum was collected and stored at -80°C for later use.
[0072] (2) Analysis of MPXV-specific binding antibodies.
[0073] Enzyme-linked immunosorbent assay (ELISA) was used to detect serum binding antibodies. The specific operation is as follows:
[0074] MPXV antigens (A35, A29, H3L, E8L, B6R, M1R) were diluted to 1 μg / mL with coating solution, and the diluted coating solution was added to a 96-well ELISA plate, incubated at 4°C overnight, washed 3 times with 1×PBST buffer, blocked with 5% milk, and incubated at 37°C for 1 hour. Serially diluted mouse serum was added, incubated at 37°C for 1 hour, washed 4 times, 100 μL of HRP goat anti-mouse IgG conjugate antibody (dilution ratio 1:5000) was added to each well, incubated at 37°C for 1 hour, washed 4 times with PBST, and 100 μL / well of color development solution was added for 5 minutes, and then 50 μL of 2 mol·L −1 The color development was terminated by sulfuric acid and the plate was read at 450 nm using an ELISA reader.
[0075] (3) Plaque reduction neutralization test (PRNT).
[0076] Neutralizing antibodies in serum samples were detected by 50% plaque reduction neutralization test (PRNT50). Serially diluted serum was incubated with VACV WR strain at 37°C for 90 minutes. After that, the virus-serum complex was transferred to BS-C-1 cells cultured in 96-well culture plates and incubated at 37°C for 90 minutes. The mixture was discarded from the cells, and mixed agar was added to each well of cells. After solidification, it was placed in a 37°C, 5% CO2 incubator for 2 days. Plaques were observed, and the cells were fixed with 4% formaldehyde solution for 30-60 minutes. After discarding the agar cover, crystal violet solution was added for staining for 10 minutes, and the residual solution was washed off. The number of viruses in the experimental group and the control group was calculated according to the number of plaques per well, and the neutralizing antibody titer PRNT50 in the serum samples was calculated by the Spearman Karber method.
[0077] Results: Antigen-specific antibody titers were determined by indirect ELISA. After three immunizations, the titers of antigen-specific antibodies were significantly higher in 9 experimental groups (MPXV6, MPXV5, MPXV4, MPXV3a, MPXV3b, MPXVFa, MPXV2a, MPXVFb, MPXV2b) containing A35 antigen. Figure 3-E , Figure 3-C , Figure 3-D), antibodies against A35 antigen were detected in all four experimental groups containing B6R antigen (MPXV6, MPXV5, MPXV4, MPXV3a), antibodies against E8L antigen were detected in the experimental group containing E8L (MPXV6), specific antibodies against M1R antigen were detected in all seven experimental groups containing M1R antigen (MPXV6, MPXV5, MPXV4, MPXV3a, MPXV3b, MPXVFa, MPXV2a), specific antibodies against A29 antigen were detected in all six experimental groups containing A29 antigen (MPXV6, MPXV5, MPXV4, MPXV3b, MPXVFb, MPXV2b), antibodies against H3L antigen were detected in all two experimental groups containing H3L antigen (MPXV6, MPXV5), but no corresponding specific antibodies were detected in the control group ( Figure 3-E The specific antibody titers against the six antigens increased after the first immunization, and the antibody titers against the corresponding antigens in the experimental groups containing the six antigens were all higher than 10 3 After the second immunization, the specific antibody titer increased further, and the specific antibody titer against H3L antigen was detected to be close to 10 in the experimental group containing H3L antigen. 5 In the experimental groups containing A35, B6R, E8L, M1R, and A29 antigens, the specific antibody titers against the corresponding antigens were all greater than 10 5 After the second immunization, the antibody titers against the corresponding antigens in the experimental groups containing 6 antigens were all higher than 10. 5 .
[0078] The specific binding antibody titer of each group of sera was tested two weeks after the third immunization. The results showed that the level remained high after the second immunization. Therefore, the neutralizing antibody titer of the sera two weeks after the second immunization was tested. The plaque reduction neutralization test (PRNT) was performed using the VACV true virus of the same genus as MPXV to detect the neutralizing antibodies in the serum. The results showed that the neutralization activity of VACV in the MPXV6 group was 1:4718, the neutralization activity of VACV in the MPXV5 group was 1:3331, the neutralization activity of VACV in the MPXV4 group was 1:2820, the neutralization activity of VACV in the MPXV3a group was 1:4022, the neutralization activity of VACV in the MPXV3b group was 1:2663, the neutralization activity of VACV in the MPXVFa group was 1:3763, and the neutralization activity of VACV in the MPXV2a group was 1:3727. High levels of neutralizing antibody titers were detected in the sera of the 7 groups of immunized mice. The neutralizing antibody titers induced by the vaccines in the MPXVFb and MPXV2b groups were about 1:380, which had neutralizing activity. The neutralizing antibody titer detected in the MPXV6 group was significantly higher than that in the MPXV4 and MPXV3b groups (P<0.05, P<0.01); there was no significant difference in the neutralizing antibody titer detected in the serum of mice immunized with MPXV6 and MPXV2a groups (P>0.05). Figure 4-A There was no significant difference in the neutralizing antibody titer detected in the serum of mice immunized with MPXVFa (A35-M1R) and that in the serum of mice immunized with MPXV2a (A35, M1R) (P>0.05). Figure 4-B There was no neutralizing activity against VACV in the sera of mice immunized in the adjuvant negative control group.
[0079] Example 4: Histopathological observation.
[0080] The six-antigen group contains the most types of antigens. As long as the safety of the MPXV6 group is proven, the safety of the other groups will meet the standards. Two weeks after the three immunizations (day 43), the heart, liver, spleen, lung, and kidney of three mice in each of the six-antigen group MPXV6 and adjuvant groups were randomly selected, their morphology was fixed with formaldehyde, and then embedded in paraffin and cut into thin slices. These slices were stained with hematoxylin and eosin, observed with an optical microscope, and histologically analyzed to evaluate the safety of the vaccine.
[0081] result: After immunization, the weight of mice was continuously monitored and the weight change curve was drawn ( Figure 5-A) to preliminarily evaluate the safety of the vaccine. The results showed that except for the MPXV6 group, which had a slight decrease in weight after the first immunization, there was no weight loss in the other groups, and the weight growth trend of the experimental group mice was basically the same as that of the control group. The external morphology and mental state of the mice were observed regularly, and no abnormal phenomena such as hair loss and mental depression were observed in the mice. In order to further evaluate the safety of the MPXV candidate vaccine, the histopathological changes of major organs such as the heart, liver, spleen, lungs, and kidneys were observed under an optical microscope. The results showed that there was no significant difference between the experimental group and the control group ( Figure 5-B ), the safety of MPXV6 in mice was further confirmed. The above results all indicate that the MPXV subunit candidate vaccine has no toxic side effects on mice and has good safety.
[0082] The above is only a preferred specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed by the present invention should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.
Claims
1. A recombinant multi-component subunit vaccine of monkeypox virus, characterized in that: It comprises a monkeypox virus recombinant protein and an adjuvant, wherein the monkeypox virus recombinant protein is one of the following combinations: (1) A35-A29, (2) A35-M1R, (3) A35 and A29, (4) A35 and M1R, (5) A35, A29 and M1R, (6) A35, M1R and B6R, (7) A35, M1R, B6R and A29, (8) A35, M1R, B6R and A29, H3L, (9) A35, M1R, B6R, H3L, E8L and A29; The amino acid sequence of A35 is shown in SEQ ID NO: 1, the amino acid sequence of B6R is shown in SEQ ID NO: 2, the amino acid sequence of E8L is shown in SEQ ID NO: 3, the amino acid sequence of A29 is shown in SEQ ID NO: 4, the amino acid sequence of M1R is shown in SEQ ID NO: 5, the amino acid sequence of H3L is shown in SEQ ID NO: 6, the amino acid sequence of A35-A29 is shown in SEQ ID NO: 7, and the amino acid sequence of A35-M1R is shown in SEQ ID NO:
8.
2. The monkeypox virus recombinant multi-component subunit vaccine according to claim 1, characterized in that: The adjuvants include aluminum hydroxide adjuvant and CpG adjuvant.
3. The biological material related to the recombinant multi-component subunit vaccine of monkeypox virus according to claim 1 is any one of the following B1) to B8): B1) a nucleic acid molecule encoding the monkeypox virus recombinant protein according to claim 1; B2) an expression cassette containing the nucleic acid molecule described in B1); B3) a recombinant vector containing the nucleic acid molecule described in B1); B4) a recombinant vector containing the expression cassette described in B2); B5) a recombinant microorganism containing the nucleic acid molecule described in B1); B6) a recombinant microorganism containing the expression cassette described in B2); B7) a recombinant microorganism containing the recombinant vector described in B3); B8) A recombinant microorganism containing the recombinant vector described in B4).
4. The biomaterial according to claim 3, characterized in that The vectors include yeast expression vectors and Escherichia coli prokaryotic expression vectors.
5. The biomaterial according to claim 3, characterized in that The recombinant microorganisms include engineered bacteria.
6. The biomaterial according to claim 5, characterized in that The engineered bacteria include yeast and Escherichia coli.
7. The biomaterial according to claim 6, characterized in that The yeast is a glycosyl engineering yeast strain.
8. A method for preparing a recombinant multi-component subunit vaccine of monkeypox virus as claimed in any one of claims 1 to 2, comprising: Obtain coding genes; transforming the coding gene into expression cells; Expressing monkeypox virus recombinant protein in expression cells; And purify the monkeypox virus recombinant protein.
9. The preparation method according to claim 8, characterized in that: The cells include yeast and / or E. coli.
10. The preparation method according to claim 9, characterized in that: The yeast is a glycosyl engineering yeast strain.
11. Use of the recombinant multi-component subunit vaccine of monkeypox virus according to any one of claims 1 to 2, or the biological material according to any one of claims 3 to 7, or the preparation method according to any one of claims 8 to 10 in any of the following C3 to C4: c3) preparing a pharmaceutical composition for preventing or treating diseases caused by infection with monkeypox virus; c4) preparing a pharmaceutical composition for preventing or treating infection by monkeypox virus; The pharmaceutical composition comprises an adjuvant.
